BUSINESS NAME

NEWSLETTER T ITLE

Diseases | Surgery of the Retina and Vitreous

WELCOMING DANIEL SU , MD

Dr. Daniel Su graduated Magna cum Laude from UCLA with a Bachelor’s degree in Electrical Engi-neering. He received his Doctor of Medicine degree from the Icahn School of Medicine at Mount Sinai in New York, where he was elected to the Alpha Omega Alpha Medical Honor Society and graduated with Distinction in Research.

Following an internship at Cedars-Sinai Medical Center in Los Angeles, he completed his residency training in ophthalmology at the Jules Stein Eye Institute at UCLA, where he was recognized both with the Jules Stein Resident Awards for Surgical Excellence and Clinical Research. He went on to com-plete a two-year vitreoretinal surgical fellowship at the renowned Wills Eye Hospital in Philadelphia, during which time he was awarded the prestigious national award from the Heed Ophthalmic Founda-tion.

Dr. Su has authored numerous peer-reviewed scientific publications and textbook chapters on vitreoretinal diseases and has

been an invited speaker to present scientific papers and abstracts at various national ophthalmic and retina subspecialty

meetings. Dr. Su is fluent in Mandarin Chinese.

INAUGURAL USC-RVA JOINT V ITREORETINAL FELLOWSHIP

To better meet the needs of our patients and extensive referral doctor net-work, we have now opened a Glendale office location!

1510 S. Central Ave., Suite 230

Glendale, CA 91204

Phone # (818) 797-4870 Fax # (818) 797-4970

NEW GLENDALE OFFICE!

X

We are excited and proud to announce that we have joined forces with the USC Roski Eye Institute to form a joint Vitreoretinal Surgical Fellowship training program. We have created a true hybrid training program, allowing fellows-in-training to experience the full gamut of vitreoretinal practice: academics, LA County Medical Center (LAC+USC), and retina-only private practice. We look to bring one of the top training programs in the country to even greater heights!

www.LAretina.com

SAVE THE DATE : ANNUAL RETINA UPDATE CONFERENCE– SUNDAY , MARCH 15, 2020

CURRENTLY ENROLLING CLINICAL TRIALS

Retina-Vitreous Associates Medical Group has participated in clinical research for over 15 years and is committed to the development of novel diagnostic and therapeutic modalities for retinal disease. All of our physicians participate in clinical trials, giving patients unique and easy access to the latest developments in treatments of vitreoretinal diseases. We are com-mitted to bettering the quality, efficacy, and ease of treatment for our patients. Transportation may be provided.

RETINITIS PIGMENTOSA (RP)

A genetic condition causing progressive vision loss. Night blindness usually occurs first, followed by peripheral, central, and color vision loss.

We offer injections of human stem cell-derived retinal progenitor cells in the office that may offer long-term visual benefits to pa-tients who otherwise have no other treatments available.

MACULAR DEGENERATION (Age-related/AMD)

The leading cause of vision loss in America, AMD is progressive disorder affecting the central vision in patients 50 years or older.

“Dry” macular degeneration: currently no treatment available.

“Wet” macular degeneration: current standard of care treatment includes frequent eye injections

We provide trials for both early and end stage dry and wet AMD using in-office as well as surgical treatments.

DIABETIC RETINOPATHY

Patients with type 1 and type 2 diabetes can suffer from damage to the blood vessels in the retina, causing mild to severe vision loss and potentially blindness.

Currently under investigation are an orally administered pill and a subcutaneous (underneath the skin) self-administered injection.

DIABETIC MACULAR EDEMA (DME)

An accumulation of swelling in the central retina that causes vision loss in diabetic patients. This is a component of diabetic retinopa-thy.

Our trials look for novel treatments for diabetic macular edema and in combination with current gold-standard treatment.

RETINAL VEIN OCCLUSION (CRVO and BRVO)

Commonly referred to as a “stroke in the eye”, a blood clot in the retinal blood vessels can cause vision loss and secondary glaucoma.

We are investigating multiple novel treatments to improve outcomes and decrease the number of necessary visits and procedures.

UVEITIS: ANTERIOR, INTERMEDIATE, POSTERIOR, AND PAN-UVEITIS

A broad term for inflammation of the eye, it can be classified based on the parts of the eye that are affected.

We offer a spectrum of treatments including eye drops, subcutaneous injections, and oral medication for various types of uveitis.

STARGARDT DISEASE NEW!

A rare genetic macular condition (ABCA4 mutation) for which we are now offering a Phase 3 treatment trial.

MACULAR TELANGIECTASIA/IDIOPATHIC JUXTAFOVEAL RETINAL TELANGIECTASIS NEW!

Another rare bilateral macular disease of unknown cause that usually causes mild to moderate vision loss.

RVA 2019 PUBLICATIONS

1. Pieramici D, Singh RP, Gibson A, Saroj N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Soo Y, Zhu X, Boyer DS. Outcomes of Diabetic Macular Edema Eyes with Limited Early Response in the VISTA and VIVID Studies. Ophthalmol Retina. 2018 Jun;2(6):558-566. 2. Mitchell P, McAllister I, Larsen M, Staurenghi G, Korobelnik JF, Boyer DS, Do DV, Brown DM, Katz TA, Berliner A, Vitti R, Zeitz O, Metzig C, Lu C, Holz FG. Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies. Ophthalmol Retina. 2018 Oct;2(10):988-996. 3. Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, Noronha G; Tanzanite Study Group. Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study. Ophthalmol Retina. 2018 Apr;2(4):320-328. 4. Khanani AM, Duker JS, Heier JS, Kaiser PK, Joondeph BC, Kozma P, Rosberger DF, MacCumber M, Boyer DS, Pieramici DJ. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study. Ophthalmol Retina. 2019 Jan;3(1):32-41. 5. Chakravarthy U, Bezlyak V, Sagkriotis A, Griner R, Skelly A, Boyer DS, Milnes F. Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence. Ophthalmol Retina. 2019 Jan;3(1):8-15.e1. 6. Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol. 2019 Jun;202:91-99. 7. Tabandeh H, London NJS, Boyer DS, Flynn HW Jr. Outcomes of small-gauge vitreoretinal surgery without scleral-depressed shaving of the vitreous base in the era of wide-angle viewing systems. Br J Ophthalmol. 2019 Feb 15. 8. Khurana RN, Rahimy E, Joseph WA, Saroj N, Gibson A, Vitti R, Berliner AJ, Chu K, Cheng Y, Boyer DS. Extended (Every 12 Weeks or Longer) Dosing Inter-val With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials. Am J Ophthalmol. 2019 Apr;200:161-168. 9. Yu JJ, Agrón E, Clemons TE, Domalpally A, van Asten F, Keenan TD, Cukras C, Chew EY; Age-Related Eye Disease Study 2 Research Group. Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17. Ophthalmolo-gy. 2019 Feb;126(2):261-273. 10. Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. Ophthalmolo-gy. 2018 Dec;125(12):1913-1928. 11. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. Payne JF, Clark WL, Bruce BB, Wykoff CC, Brown DM, Menke BM, Iverson SM, Allen KF, Boyer DS; Treat & Extend Protocol in Patients with Diabetic Macular Edema Study Group. Ophthalmology. 2018 Aug;125(8):1304-1306. 12. Rosenfeld PJ, Dugel PU, Holz FG, Heier JS, Pearlman JA, Novack RL, Csaky KG, Koester JM, Gregory JK, Kubota R. Emixustat Hydrochloride for Geo-graphic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial. Ophthalmology. 2018 Oct;125(10):1556-1567. 13. Su D, Stephens JD, Obeid A, Borkar D, Storey PP, Khan MA, Hsu J, Garg SJ, Gupta O. Refractive Outcomes after Pars Plana Vitrectomy and Scleral Fixated Intraocular Lens with Gore-Tex Suture. Ophthalmol Retina. 2019 Jul;3(7):548-552. 14. Storey PP, Pancholy M, Wibbelsman TD, Obeid A, Su D, Borkar D, Garg S, Gupta O. Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor. Ophthalmology. 2019 Apr 28. pii: S0161-6420(18)33327-X. 15. Garrity ST, Jung JY, Zambrowski O, Pichi F, Su D, Arya M, Waheed NK, Duker JS, Chetrit Y, Miserocchi E, Giuffrè C, Kaden TR, Querques G, Souied EH, Freund KB, Sarraf D. Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects. Br J Ophthal-mol. 2019 Feb 28. pii: bjophthalmol-2018-313350. 16. Su D, Obeid A, Hsu J. Topical Aqueous Suppression and Closure of Idiopathic Full-Thickness Macular Holes. Ophthalmic Surg Lasers Imaging Retina. 2019 Feb 1;50(2):e38-e43. 17. Su D, Borkar D, Gupta O. Scleral Fixation of Posterior Chamber Hydrophobic Acrylic Intraocular Lenses Using Gore-Tex Suture. Retina. 2019 Apr 24. 18. Storey PP, Obeid A, Pancholy M, Goodman J, Borkar D, Su D, Regillo C. OCULAR HYPERTENSION AFTER INTRAVITREAL INJECTION OF 2-MG TRIAMCINOLONE. Retina. 2018 Oct 9. 19. Su D, Garg S. The retinal function imager and clinical applications. Eye Vis (Lond). 2018 Aug 12;5:20. 20. Obeid A, Su D, Patel SN, Uhr JH, Borkar D, Gao X, Fineman MS, Regillo CD, Maguire JI, Garg SJ, Hsu J. Outcomes of Eyes Lost to Follow-up with Prolif-erative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor. Ophthalmology. 2019 Mar;126(3):407-413. 21. Borkar DS, Obeid A, Su DC, Storey PP, Gao X, Regillo CD, Kaiser RS, Garg SJ, Hsu J; Wills Post Injection Endophthalmitis (PIE) Study Group. Endophthal-mitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2018 Oct;194:1-6. 22. Su D, Obeid A, Hsu J. External Drainage of Subretinal Fluid During Vitrectomy for Rhegmatogenous Retinal Detachment. Retina. 2019 Mar 28. 23. Chae B, Su D, Gal-Or O, Freund KB, Sarraf D. Type 3 neovascularisation: long-term analysis of visual acuity and optical coherence tomography anatomical outcomes. Br J Ophthalmol. 2019 Jan;103(1):43-48. 24. Sastry A, Kwon JY, Tan JJ, Rodger DC, Rao NA. Endogenous Aspergillus endophthalmitis in an immunocompetent patient with a remote history of pulmo-nary tuberculosis. Retinal Cases & Brief Reports. 2019 July.

CONTACT INFORMATION

Main Phone: (213) 483-8810 Clinical Trials Center: (310) 289-2478 x3

www.LAretina.com Clinical Trials Fax: (310) 652-1956

Beverly Hills 9001 Wilshire Blvd., Suite 301 Beverly Hills, CA 90211 Phone: (310) 854-6201 FAX: (310) 652-7520

Los Angeles 1245 Wilshire Blvd., Suite 380 Los Angeles, CA 90017 Phone: (213) 483-8810 FAX: (213) 481-1503

North Hollywood 12840 Riverside Drive, Suite 333 North Hollywood, CA 91607 Phone: (818) 754-2090 FAX: (818) 508-9420

Pasadena 301 S. Fair Oaks Ave, Suite 407 Pasadena, CA 91105 Phone: (626) 204-1410 Fax: (626) 204-1420

Tarzana 5525 Etiwanda Ave. Suite 112 Tarzana, CA 91356 Phone: (818) 578-7408 FAX: (818) 578-7409

Torrance 3400 Lomita Blvd., Suite 202 Torrance, CA 90505 Phone: (310) 891-1000 FAX: (310) 891-1003

Daniel D. Esmaili, MD Alexander C. Walsh, MD Jeffrey J. Tan, MD David S. Liao, MD

Richard H. Roe, MD

Pouya N. Dayani, MD

David S. Boyer, MD Roger L. Novack, MD Thomas G. Chu, MD Firas M. Rahhal, MD Homayoun Tabandeh, MD

Daniel Su, MD

“This is hands down a world class retina hub! ...I was super nervous about everything but walked out feeling much calmer than when I went in. On top of the incredible care they provide for their pa-tients, they also have a nonprofit foundation ... as well as conducting research to help find treatments for incur-able retinal diseases. Big thumbs up and thank you so much for what you do!”

- Tony D., Victorville, CA

"Best possible experience! ... He was incredibly knowledgeable and had a wonder-ful bedside manner.

Long story short he was able to give me a 99% sure diagnoses and calmed me down... I could not have had a better experience and would highly recommend them to everyone. Thank you RVA Group! "

- Kimberly S., Los Angeles, CA

WHAT PEOPLE ARE SAYING ABOUT US

We are committed to providing our clients with a positive experience, your feedback helps make that possible. Thank you!

www.LAretina.com